期刊文献+

穿琥宁肠溶胶囊在犬体内的药物动力学及绝对生物利用度 被引量:2

Pharmacokinetics and bioavailability of Kalii Dehydrograpolidi Succinatis Enteric capsules in plasma of dog
下载PDF
导出
摘要 目的 研究穿琥宁肠溶胶囊在犬体内的药物动力学及绝对生物利用度。方法 家犬 6只 ,随机分为 2组 ,采用单剂量交叉给药方案 ,分别给犬单剂量静脉注射或口服穿琥宁肠溶胶囊 ,用HPLC法测定给药后的血中药物浓度 ,3p97药动学程序处理。结果 穿琥宁肠溶胶囊的药 -时数据符合二室模型 ,Cmax为 2 4 .3μg·ml-1,Tmax为 1.2 6h ,AUC(0→∞ ) 为 2 92 84 μg·ml-1,绝对生物利用度为 30 .0 3%。 OBJECTIVE To study the pharmacokinetics and bioavailability of Kalii Dehydrograpolidi Succinatis Enteric capsules in plasma of dog.METHODS A single dose of Kalii Dehydrograpolidi Succinatis were iv or orally given to 6 dogs in an open randomized crossover test. HPLC was selected to determine the concentration of Kalii Dehydrograpolidi Succinatis in serum. The pharmacokinetic parameters of Kalii Dehydrograpolidi Succinatis enteric capsules was calculated and analysed by 3p97 program.RESULTS The disposition was conformed to a two-compartment model.The T max , C max , AUC 0→∞ and Absolut bioavailability of Kalii Dehydrograpolidi Succinatis enteric capsules were 24.3 μg·ml -1 ,1.26 h ,29284 μg·ml -1 ·h and 30.03%.CONCLUSION Kalii Dehydrograpolidi Succinatis enteric capsules has a good bioavailability.
出处 《华西药学杂志》 CAS CSCD 2003年第2期101-103,共3页 West China Journal of Pharmaceutical Sciences
关键词 穿琥宁肠溶胶囊 药物代谢动力学 生物利用度 HPLC法 动物实验 Pharmacokinetics Bioavailability Kalii Dehydrograpolidi Succinatis Enteric capsules
  • 相关文献

参考文献2

二级参考文献4

共引文献37

同被引文献18

  • 1唐振香,苗青原.药物靶向制剂的研究进展[J].中国药事,2007,21(8):628-630. 被引量:4
  • 2Li SJ,Yang D,Zhang MQ. Determination of dehydroandrographolide succinate in human plasma by liquid chromatography tandem mass spectrometry (LC-MS/MS):method development,validation and clinical pharmacokinetic study[J].Journal of Chromatography B:Biomedical Applications,2010,(24):2274-2279.
  • 3Zhang J,Cage EM,Ji QC. A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography/tandem mass spectrometric detection[J].Rapid Communications in Mass Spectrometry,2007,(14):2169-2176.doi:10.1002/rcm.3046.
  • 4FDA. Guidance for industry:bioanalytical methods validation[EB/OL].http:.//www.fda.gov/downloadd/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf,2012.
  • 5Matuszewski BK,Constanzer ML,Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS[J].Analytical Chemistry,2003,(13):3019-3030.doi:10.1021/ac020361s.
  • 6李志强,唐楷.阿魏酸钠肠溶胶囊:中国,200920080021.3[P].2010-05-12.
  • 7杨玮,李纯球,刘华钢,等.大蒜素B环糊精包合物的研究[J].中国药科大学学报,1987,18(4):293-295.
  • 8Battino D, Biraghi M, Cusi C, et at. Comparison of the effectiveness of several formulations of sodium valproate : tablets, enteric - coated capsules, solutions and rectal capsules [ J ]. Italian Journal of Neurological Sciences, 1982,3 ( 3 ) : 197-200.
  • 9贾毅,朱光耀,何福银,等.一种全自动肠溶胶囊生产线[P].中国,201420759742.3,2015-08-05.
  • 10Lorenzo Lamosa ML, Remunan Lopz C, Vila Jato JL, et al. Journal of Controlled release, 1998, 52 : 109 -114.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部